Protein Ingredients 2018 Global Key Players – Solae, Solbar, Nutripea Market Analysis and Forecast to 2022

Protein Ingredients Market Consumption 2018 Forecast to 2022

PUNE, INDIA, June 19, 2018 /EINPresswire.com/ — Protein ingredients are large molecules which are formed from one or more chains of amino acids in a specific order. The order is determined by the base sequence of nucleotides in the genes that compose the protein. Protein ingredients are essential for structure, function, and regulation of body’s cells, tissue, and various organs. There are different types of protein ingredients which help to enhance the functionality of hormones, enzymes, and antibodies. Protein ingredients contain a broad range of both plant and animal based protein in different forms.

GET SAMPLE REPORT @ https://www.wiseguyreports.com/sample-request/3008156-global-protein-ingredients-market-research-report-forecast-to-2022

Globally, plant proteins have witnessing less demand which is driving higher private investments by companies involved in the Protein Ingredients market to gain consumer attention and encourage buying. Companies who manufacture plant-based protein from North America and Europe are spending more on marketing activities to promote plant protein as animal protein are very popular among the consumer groups in those particular areas. Increase in the expenditure by companies involved in protein ingredients supply backed by growing awareness among consumers will continue to drive higher demand for protein ingredients.

Rapid advancements have been noticed in the protein ingredients products starting from the various inclusions of raw materials to packaging. Various factors such as taste, quality, and source of protein are critical for protein ingredients market. Manufacturers of protein ingredients have adopted suitable technologies to achieve desired taste and texture according to consumer’s preferences. The advancements in technology have resulted in the introduction of a wide variety of protein ingredient products to the consumers with different delivery formats, taste and sources and thereby driving Protein Ingredients market.

Regional Analysis:
The global protein ingredients market is segmented into North America, Europe, Asia Pacific, and Rest of the World. North America & Europe are collectively accounting for 70% market proportion in the year of 2017. North America is projected to grow at a CAGR of about 5.22% and Europe at 2.02% for the period 2017-2022. Asia-Pacific region is projected to grow the most at a CAGR of about 5.66% for the period 2017-2022.

Segments:
Protein ingredients market has been segmented on the basis of feedstock which comprises of soy, wheat, pea, canola, whey, milk, casein, egg, beef, pork, and others. On the basis of form, protein ingredients market has been segmented into powder, bars, ready to drink, capsules & tablets, and others. Protein ingredients market has been segmented by application such as functional foods, sports nutrition, meat additives, confectionery & other Food Products, pharmaceuticals, and others

Key Players:
The leading market players in the global protein ingredients market primarily are Archer-Daniels-Midland Co. (U.S.), Solae (U.S.), Shandong Yuwang Industrial Co., Ltd (China), Shandong Sinoglory Health Food Co., Ltd (China), Gushen Biological Technology Group Co., Ltd (China), Solbar (Israel) and Nutripea (Canada)

Target Audience:
• Food & beverages manufacturers
• Protein ingredients manufacturers
• Raw material suppliers
• End users (food & beverages industry)
• Retailers and wholesalers
• E-commerce companies
• Traders, importers, and exporters

Key Findings:
• Whey & soy protein is estimated to account for the significant market share in the year of 2017. The trend is expected to continue throughout the forecast period
• Among the application, Functional foods and sports nutrition currently dominate the market and will continue to be the major end-use markets for protein ingredients with projected share together of about 58.4% by 2022.

Regional and Country Analysis of protein ingredients Market Development and Demand Forecast to 2022 Market:
As per the MRFR analysis, the global protein ingredients market is poised to reach 5,547.12 kilotons in 2022, to grow at a CAGR of 3.87% during the forecasted period.

Table of Content: Key Points
1 Executive Summary 15
2 Introduction 16
2.1 Definition 16
2.2 Scope of the Study 16
2.3 Market Structure 16
3 Research Methodology 19
3.1 Introduction 19
3.2 Primary Research 20
4 Secondary Research 21
5 Market Dynamics 22
5.1 Introduction 22
5.1.1 Drivers 22
5.1.2 Functional Properties 23
5.1.3 Advancement in technology 23
5.1.4 Restraints 23
5.1.5 Opportunities 24
5.1.6 Challenges 24
6 Market Trends 26
7 Emerging markets for proteins 29
…Continued

ACCESS REPORT @ https://www.wiseguyreports.com/reports/3008156-global-protein-ingredients-market-research-report-forecast-to-2022

Get in touch:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire

Global Implantable Neurostimulators Market 2018 Share, Trend, Segmentation and Forecast to 2023

Implantable Neurostimulators Market 2018 Global Analysis, Growth, Trends and Opportunities Research Report Forecasting to 2023

PUNE, MAHARASHTRA, INDIA, June 19, 2018 /EINPresswire.com/ — Summary

WiseGuyReports.com adds “Implantable Neurostimulators Market 2018 Global Analysis, Growth, Trends and Opportunities Research Report Forecasting to 2023” reports to its database.

This report provides in depth study of “Implantable Neurostimulators Market” using SWOT analysis i.e. Strength, Weakness, Opportunities and Threat to the organization. The Implantable Neurostimulators Market report also provides an in-depth survey of key players in the market which is based on the various objectives of an organization such as profiling, the product outline, the quantity of production, required raw material, and the financial health of the organization.

This report studies the global Implantable Neurostimulators market status and forecast, categorizes the global Implantable Neurostimulators market size (value & volume) by key players, type, application, and region. This report focuses on the top players in North America, Europe, Asia-Pacific, South America, and Middle East & Africa.

The major manufacturers covered in this report
Medtronic
Boston Scientific
St. Jude Medical
Cyberonics
NeuroPace
Synapse Biomedical
NeuroSigma
EnteroMedics
ElectroCore Medical
Inspire Medical
NEUROS
SPR
IMTHERA
NEVRO

Geographically, this report studies the key regions, focuses on product sales, value, market share and growth opportunity in these regions, covering
North America
Europe
China
Japan
Southeast Asia
India

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into
Deep Brain Stimulators
Spinal Cord Stimulators
Vagal Nerve Stimulators
Sacral Nerve Stimulators
Gastric Stimulators
Others

On the basis of the end users/applications, this report focuses on the status and outlook for major applications/end users, consumption (sales), market share and growth rate for each application, including
Parkinson's Disease
Epilepsy
Pain
Others

Request a Sample Report @ https://www.wiseguyreports.com/sample-request/3232733-global-implantable-neurostimulators-market-research-report-2018

Major Key Points in Table of Content

Global Implantable Neurostimulators Market Research Report 2018
1 Implantable Neurostimulators Market Overview
1.1 Product Overview and Scope of Implantable Neurostimulators
1.2 Implantable Neurostimulators Segment by Type (Product Category)
1.2.1 Global Implantable Neurostimulators Production and CAGR (%) Comparison by Type (Product Category)(2013-2025)
1.2.2 Global Implantable Neurostimulators Production Market Share by Type (Product Category) in 2017
1.2.3 Deep Brain Stimulators
1.2.4 Spinal Cord Stimulators
1.2.5 Vagal Nerve Stimulators
1.2.6 Sacral Nerve Stimulators
1.2.7 Gastric Stimulators
1.2.8 Others
1.3 Global Implantable Neurostimulators Segment by Application
1.3.1 Implantable Neurostimulators Consumption (Sales) Comparison by Application (2013-2025)
1.3.2 Parkinson's Disease
1.3.3 Epilepsy
1.3.4 Pain
1.3.5 Others
1.4 Global Implantable Neurostimulators Market by Region (2013-2025)
1.4.1 Global Implantable Neurostimulators Market Size (Value) and CAGR (%) Comparison by Region (2013-2025)
1.4.2 North America Status and Prospect (2013-2025)
1.4.3 Europe Status and Prospect (2013-2025)
1.4.4 China Status and Prospect (2013-2025)
1.4.5 Japan Status and Prospect (2013-2025)
1.4.6 Southeast Asia Status and Prospect (2013-2025)
1.4.7 India Status and Prospect (2013-2025)
1.5 Global Market Size (Value) of Implantable Neurostimulators (2013-2025)
1.5.1 Global Implantable Neurostimulators Revenue Status and Outlook (2013-2025)
1.5.2 Global Implantable Neurostimulators Capacity, Production Status and Outlook (2013-2025)

……

7 Global Implantable Neurostimulators Manufacturers Profiles/Analysis
7.1 Medtronic
7.1.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
7.1.2 Implantable Neurostimulators Product Category, Application and Specification
7.1.2.1 Product A
7.1.2.2 Product B
7.1.3 Medtronic Implantable Neurostimulators Capacity, Production, Revenue, Price and Gross Margin (2013-2018)
7.1.4 Main Business/Business Overview
7.2 Boston Scientific
7.2.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
7.2.2 Implantable Neurostimulators Product Category, Application and Specification
7.2.2.1 Product A
7.2.2.2 Product B
7.2.3 Boston Scientific Implantable Neurostimulators Capacity, Production, Revenue, Price and Gross Margin (2013-2018)
7.2.4 Main Business/Business Overview
7.3 St. Jude Medical
7.3.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
7.3.2 Implantable Neurostimulators Product Category, Application and Specification
7.3.2.1 Product A
7.3.2.2 Product B
7.3.3 St. Jude Medical Implantable Neurostimulators Capacity, Production, Revenue, Price and Gross Margin (2013-2018)
7.3.4 Main Business/Business Overview
7.4 Cyberonics
7.4.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
7.4.2 Implantable Neurostimulators Product Category, Application and Specification
7.4.2.1 Product A
7.4.2.2 Product B
7.4.3 Cyberonics Implantable Neurostimulators Capacity, Production, Revenue, Price and Gross Margin (2013-2018)
7.4.4 Main Business/Business Overview
7.5 NeuroPace
7.5.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
7.5.2 Implantable Neurostimulators Product Category, Application and Specification
7.5.2.1 Product A
7.5.2.2 Product B
7.5.3 NeuroPace Implantable Neurostimulators Capacity, Production, Revenue, Price and Gross Margin (2015-2018)
7.5.4 Main Business/Business Overview
7.6 Synapse Biomedical
7.6.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
7.6.2 Implantable Neurostimulators Product Category, Application and Specification
7.6.2.1 Product A
7.6.2.2 Product B
7.6.3 Synapse Biomedical Implantable Neurostimulators Capacity, Production, Revenue, Price and Gross Margin (2013-2018)
7.6.4 Main Business/Business Overview
7.7 NeuroSigma
7.7.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
7.7.2 Implantable Neurostimulators Product Category, Application and Specification
7.7.2.1 Product A
7.7.2.2 Product B
7.7.3 NeuroSigma Implantable Neurostimulators Capacity, Production, Revenue, Price and Gross Margin (2013-2018)
7.7.4 Main Business/Business Overview
7.8 EnteroMedics
7.8.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
7.8.2 Implantable Neurostimulators Product Category, Application and Specification
7.8.2.1 Product A
7.8.2.2 Product B
7.8.3 EnteroMedics Implantable Neurostimulators Capacity, Production, Revenue, Price and Gross Margin (2013-2018)
7.8.4 Main Business/Business Overview
7.9 ElectroCore Medical
7.9.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
7.9.2 Implantable Neurostimulators Product Category, Application and Specification
7.9.2.1 Product A
7.9.2.2 Product B
7.9.3 ElectroCore Medical Implantable Neurostimulators Capacity, Production, Revenue, Price and Gross Margin (2013-2018)
7.9.4 Main Business/Business Overview
7.10 Inspire Medical
7.10.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
7.10.2 Implantable Neurostimulators Product Category, Application and Specification
7.10.2.1 Product A
7.10.2.2 Product B
7.10.3 Inspire Medical Implantable Neurostimulators Capacity, Production, Revenue, Price and Gross Margin (2013-2020)
7.10.4 Main Business/Business Overview
7.11 NEUROS
7.12 SPR
7.13 IMTHERA
7.14 NEVRO

At any Query @ https://www.wiseguyreports.com/enquiry/3232733-global-implantable-neurostimulators-market-research-report-2018

Continued….

Contact Us: sales@wiseguyreports.com

Ph: +1-646-845-9349 (US) ; Ph: +44 208 133 9349 (UK)

Norah Trent
WiseGuy Research Consultants Pvt. Ltd.
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire

Global Human Micobiome Market 2018 Share, Trend, Segmentation and Forecast to 2023

Human Micobiome Market 2018 Global Analysis, Growth, Trends and Opportunities Research Report Forecasting to 2023

PUNE, MAHARASHTRA, INDIA, June 19, 2018 /EINPresswire.com/ — Summary

WiseGuyReports.com adds “Human Micobiome Market 2018 Global Analysis, Growth, Trends and Opportunities Research Report Forecasting to 2023” reports to its database.

This report provides in depth study of “Human Micobiome Market” using SWOT analysis i.e. Strength, Weakness, Opportunities and Threat to the organization. The Human Micobiome Market report also provides an in-depth survey of key players in the market which is based on the various objectives of an organization such as profiling, the product outline, the quantity of production, required raw material, and the financial health of the organization.

This report studies the global Human Micobiome market size, industry status and forecast, competition landscape and growth opportunity. This research report categorizes the global Human Micobiome market by companies, region, type and end-use industry.

In 2017, the global Human Micobiome market size was 170 million US$ and it is expected to reach 820 million US$ by the end of 2025, with a CAGR of 21.7% during 2018-2025.

This report focuses on the global top players, covered
Vedanta
Seres Therapeutics
Second Genome
Rebiotix
ActoGeniX
Enterome BioScience
AvidBiotics
4D Pharma Research Ltd
Enterologics
Metabogen
Metabiomics
Ritter Pharmaceuticals
Osel
Symberix
Miomics
Symbiotix Biotherapies
MicroBiome Therapeutics LLC

Market segment by Regions/Countries, this report covers
United States
Europe
China
Japan
Southeast Asia
India

Market segment by Type, the product can be split into
Gastrointestinal Tract Human Micobiome
Urogenital Tract Human Micobiome
Other

Market segment by Application, split into
Treatment
Diagnosis

Request a Sample Report @ https://www.wiseguyreports.com/sample-request/3232729-global-human-micobiome-market-size-status-and-forecast-2025

Major Key Points in Table of Content

Global Human Micobiome Market Size, Status and Forecast 2025
1 Industry Overview of Human Micobiome
1.1 Human Micobiome Market Overview
1.1.1 Human Micobiome Product Scope
1.1.2 Market Status and Outlook
1.2 Global Human Micobiome Market Size and Analysis by Regions (2013-2018)
1.2.1 United States
1.2.2 Europe
1.2.3 China
1.2.4 Japan
1.2.5 Southeast Asia
1.2.6 India
1.3 Human Micobiome Market by Type
1.3.1 Gastrointestinal Tract Human Micobiome
1.3.2 Urogenital Tract Human Micobiome
1.3.3 Other
1.4 Human Micobiome Market by End Users/Application
1.4.1 Treatment
1.4.2 Diagnosis

2 Global Human Micobiome Competition Analysis by Players
2.1 Human Micobiome Market Size (Value) by Players (2013-2018)
2.2 Competitive Status and Trend
2.2.1 Market Concentration Rate
2.2.2 Product/Service Differences
2.2.3 New Entrants
2.2.4 The Technology Trends in Future

3 Company (Top Players) Profiles
3.1 Vedanta
3.1.1 Company Profile
3.1.2 Main Business/Business Overview
3.1.3 Products, Services and Solutions
3.1.4 Human Micobiome Revenue (Million USD) (2013-2018)
3.2 Seres Therapeutics
3.2.1 Company Profile
3.2.2 Main Business/Business Overview
3.2.3 Products, Services and Solutions
3.2.4 Human Micobiome Revenue (Million USD) (2013-2018)
3.3 Second Genome
3.3.1 Company Profile
3.3.2 Main Business/Business Overview
3.3.3 Products, Services and Solutions
3.3.4 Human Micobiome Revenue (Million USD) (2013-2018)
3.4 Rebiotix
3.4.1 Company Profile
3.4.2 Main Business/Business Overview
3.4.3 Products, Services and Solutions
3.4.4 Human Micobiome Revenue (Million USD) (2013-2018)
3.5 ActoGeniX
3.5.1 Company Profile
3.5.2 Main Business/Business Overview
3.5.3 Products, Services and Solutions
3.5.4 Human Micobiome Revenue (Million USD) (2013-2018)
3.6 Enterome BioScience
3.6.1 Company Profile
3.6.2 Main Business/Business Overview
3.6.3 Products, Services and Solutions
3.6.4 Human Micobiome Revenue (Million USD) (2013-2018)
3.7 AvidBiotics
3.7.1 Company Profile
3.7.2 Main Business/Business Overview
3.7.3 Products, Services and Solutions
3.7.4 Human Micobiome Revenue (Million USD) (2013-2018)
3.8 4D Pharma Research Ltd
3.8.1 Company Profile
3.8.2 Main Business/Business Overview
3.8.3 Products, Services and Solutions
3.8.4 Human Micobiome Revenue (Million USD) (2013-2018)
3.9 Enterologics
3.9.1 Company Profile
3.9.2 Main Business/Business Overview
3.9.3 Products, Services and Solutions
3.9.4 Human Micobiome Revenue (Million USD) (2013-2018)
3.10 Metabogen
3.10.1 Company Profile
3.10.2 Main Business/Business Overview
3.10.3 Products, Services and Solutions
3.10.4 Human Micobiome Revenue (Million USD) (2013-2018)
3.11 Metabiomics
3.12 Ritter Pharmaceuticals
3.13 Osel
3.14 Symberix
3.15 Miomics
3.16 Symbiotix Biotherapies
3.17 MicroBiome Therapeutics LLC

4 Global Human Micobiome Market Size by Type and Application (2013-2018)
4.1 Global Human Micobiome Market Size by Type (2013-2018)
4.2 Global Human Micobiome Market Size by Application (2013-2018)
4.3 Potential Application of Human Micobiome in Future
4.4 Top Consumer/End Users of Human Micobiome

At any Query @ https://www.wiseguyreports.com/enquiry/3232729-global-human-micobiome-market-size-status-and-forecast-2025

Continued….

Contact Us: sales@wiseguyreports.com

Ph: +1-646-845-9349 (US) ; Ph: +44 208 133 9349 (UK)

Norah Trent
WiseGuy Research Consultants Pvt. Ltd.
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire

M-health Device Industry Business & Investment Opportunity (2018 – 2022) Market Research Reports

M-health Device Market 2018 Global Industry Analysis, Opportunities and Forecast To 2023

PUNE, INDIA, June 19, 2018 /EINPresswire.com/ — Introduction
mHealth or mobile health, are used for the practice of medicine and public health supported by mobile devices. M-Health enables various electronic health (e-health) data content and services to users, by using wireless technologies such as WiMax, Bluetooth, GSM/GPRS/3G, and WiFi among others. These devices are deployed for monitoring, diagnosis, and treatment applications that augment the chances of better healthcare and fitness systems. These devices work as a guiding framework to record the data by the patient and send it to the healthcare providers for feedback.

GET SAMPLE REPORT @ https://www.wiseguyreports.com/sample-request/2530944-global-m-health-device-market-estimation-forecast-2017-2023

The global M-health device market is expected to reach USD 48,663.2 million by 2023 at a CAGR of 35.03% during the forecasted period.
The global M-health device market is segmented on the basis of types, application and regions. On the basis of types, the market is segmented into: medical devices, health & fitness devices, and others. The medical devices segment market accounts the largest share and is expected to reach USD 39,530.4 million by 2023 from USD 4,752.5 million in 2016 at the CAGR of 34.89 % for the forecasted periods.
On the basis on application, the global M-health device market is segmented into monitoring, diagnosis and treatment, education and awareness, healthcare management, prevention and wellness and others. Monitoring application of m-health device dominated the global market in 2016 and accounted for USD 3,485.0 million and it is due to increasing deployment of m-health device solutions by healthcare providers and workers.
On the basis of regions, the market is segmented into North America, Europe, Asia-Pacific and the Middle East & Africa. North America has the dominating market for M-health device. The M-health device market for North America is estimated at USD 2,052.9 million in 2016 and expected to reach by USD 16,443.4 million by 2023 at a fastest CAGR of 34.16%.

Key Players
The leading market players in the global M-health device market include GE Healthcare, Apple Inc., Philips, Athenahealth, Cerner, Medtronics, Apple Inc, and Allscripts.

Study objectives
• To provide detailed analysis of the market structure along with forecast of the various segments and sub-segments of the global M-health device market
• To provide insights about factors influencing and affecting the market growth
• To provide historical and forecast revenue of the market segments and sub-segments with respect to countries
• To provide historical and forecast revenue of the market segments based on channels, applications, and regions for the global M-health device market.
• To provide strategic profiling of key players in the market, and comprehensively analysing their market share, core competencies, and drawing a competitive landscape for the market
• To provide economical factors that influences the global M-health device market
• To provide detailed analysis of the value chain and supply chain of the global M-health device market

Target Audience
• Pharmaceutical Companies
• Pharmaceutical Suppliers
• Potential investors
• Key executive (CEO and COO) and strategy growth manager
• Reaserch companies

Key Findings
• North America accounted for the largest market share in the global M-health device market, registering USD 2,052.9 million in 2016 and expected to reach by USD 16,443.4 million by 2023 at a CAGR of 34.16%
• The medical devices segment market accounts the largest share and is expected to reach USD 39,530.4 million by 2023 from USD 4,752.5 million in 2016 at the CAGR of 34.89 %
• Monitoring application of m-health device dominated the global market in 2016 and accounted for USD 3,485.0 million

Table of Content: Key Points
1 Report Prologue 11
2 Introduction 14
3 Research Methodology 16
4 Market Dynamics 18
5 Market Factor Analysis 24
6 Global M-Health Device Market, By Type 30
7 Global M-Health Device Market, By Application 35
…Continued

ACCESS REPORT @ https://www.wiseguyreports.com/reports/2530944-global-m-health-device-market-estimation-forecast-2017-2023

Get in touch:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire

SiO4 and RoboCyberWall Sign Exclusive Global Reseller Agreement

Agreement Enables Organizations to Purchase RoboCyberWall's Root Shield Software to Prevent Breaches of Apache2 and NGINX Web Server's HTTP and HTTPS Ports

“RoboCyberWall delivers optimal protection of web applications running on Apache2 and
NGINX servers,””

— Andrew Speakmaster

HOUSTON, TEXAS, UNITED STATES OF AMERICA, June 19, 2018 /EINPresswire.com/ — SiO4 Corporate Contact:
Byron Rashed
SiO4 Limited
+44 (0)845 388 0559 Main
+1 949 889 3075 Direct
byron.rashed@sio4-group.com

RoboCyberWall Corporate Contact:
John Martinson, Sr.
RoboCyberWall Inc.
+ 1 713 589 2537
+ 1 713 252 7561 Direct
john.martinson.sr@robocyberwall,com

LONDON, UK & HOUSTON, Texas – June 19, 2018 – SiO4 Limited an industry-leading
provider of specialised advanced cyber threat intelligence services, today announced a global
reseller agreement with RoboCyberWall Inc., a developer of server-based cyber security
software that protects HTTP and SSL/HTTPS ports and system root directories on Apache2 and
NGINX web servers. SiO4 will exclusively resell the award-winning RootShield TM by
RoboCyberWall TM as a stand-alone solution to their customers and will fully support the
product’s global marketing and sales efforts.

Root Shield is a unique server-based cyber security software that blocks exploits, including
zero-day attacks from breaching Apache2 and NGINX http and https ports that is seamless and
straightforward to deploy. The award-winning product works in real-time to block attacks before
they compromise the server. RootShield keeps hackers from determining web application
vulnerabilities by blocking access to the web servers’ root directory and change log files via
Directory Traverse Attacks. RootShield has a minimal footprint without any modification to the
existing infrastructure and does not impact legitimate internet traffic and has been thoroughly
tested with no measurable latency that can affect system performance. By accessing log files,
users can easily identify any blocked packets by RootShield.

“RoboCyberWall delivers optimal protection of web applications running on Apache2 and
NGINX servers,” said Andrew Speakmaster, CTO and Founder of SiO4. “As we greatly expand
our global presence, SiO4 can now provide a flexible and scalable solution that delivers real-
time updates to mitigate known and zero-day vulnerabilities to any organization in the world.
This is extremely important to international companies that need to adhere to GDPR and other
regulations to protect against potentially huge financial losses and mitigate risk.”
RoboCyberWall can prevent attacks like the infamous Equifax breach that occurred in May of
2017 due to a vulnerability in Apache Struts web application software that was left unpatched.
Approximately 83% of all web servers are Linux Apache or NGINX Linux servers that are
running critical web applications. Port 80 (HTTP) and Port 443 (SSL/HTTPS) are targets for
brute force and all known and unknown vulnerabilities. RoboCyberWall enables immediate
validation of legitimate known packets and blocks unknown packets resulting in zero false
positives and no pass through of bad packets to the server.

“We are pleased to sign this agreement with SiO4 to introduce our award-winning Root Shield
by RoboCyberWall product to their prospects and customers,” said Chris Melson, CEO of
RoboCyberWall Inc. “There is a huge need in the market to deliver this high-value product
globally since the most commonly used web servers are Apache2 or NGINX. RoboCyberWall
will not only add value to SiO4’s current product portfolio but offer a vital product to the market
to help protect their business-critical web applications.”

Product Pricing and Availability
RoboCyberWall is available immediately from SiO4. To request pricing for EMEA, please
contact SiO4 at +44 (0)845 388 0559, and for the Americas contact us at +1 949 899 3075, or
email sales@sio4-group.com. Visit the SiO4 website at https://www.sio4-group.com for more
information.

About SiO4
SiO4 provides specialised advanced cyber threat intelligence services, not threat information
like other vendors. With an elite team of operatives and researchers that engage threat actors in
the Dark Web and underground economy, SiO4 delivers comprehensive, actionable and
contextual threat intelligence focusing on preemptive breach intelligence, network exposure,compromised data, risk mitigation, social engineering, employee/physical location vulnerabilities
and Dark Web surveillance in a cost-effective and scalable modular set of real-time services
that act as an extension of an organisation’s IT security team. SiO4 prides itself on delivering
excellence to its clients by meeting their exacting cyber threat intelligence needs. Protection is
mandatory, detection and prevention are everything. For more information, please
visit http://www.sio4-group.com/.

About RoboCyberWall, Inc.
RoboCyberWall, Inc. (“RCW”) is a provider of award-winning server-based cyber security
software that protects HTTP and SS/HTTPS ports and system root directories on Apache2 and
NGINX web servers. Root Shield TM protects web application from being hacked by preventing a
hacker from gaining access to the root directories and change log file. RootShield prevents
hackers from gaining control of servers by eliminating a path into the server using a known or
unknown (“zero-day”) exploit. The technology is able to validate legitimate packets and block
illegitimate packets though real time monitoring and dynamic inspection with no measurable
latency. The patent pending technology protects from the vast majority of attacks, including
zero-day attacks and acts as a last line of defense from hackers that have penetrated the user’s
network security. RootShield is available as part of a secure Linux environment or in binary form
for inclusion in the most common Linux variants and can be incorporated into virtually any user’s
Linux environment. RootShield is easy to deploy and runs seamlessly.

Copyright © 2017-2018 SiO4 Limited. All rights reserved. All other names and trademarks are property of their respective owners.
# # #

Byron Rashed
SiO4
+1 949 889 3075
email us here


Source: EIN Presswire

Global Sanitary Napkin for Feminine Care Market 2018 To Grow At A 7.61% Cagr Analysis And Forecast To 2025

Sanitary Napkin for Feminine Care – Global Market Demand, Growth, Opportunities, Manufacturers, Analysis of Top Key Players and Forecast to 2025

PUNE, MAHARASHTRA, INDIA, June 19, 2018 /EINPresswire.com/ — Sanitary Napkin for Feminine Care Market 2018

Wiseguyreports.Com Adds “Sanitary Napkin for Feminine Care – Global Market Demand, Growth, Opportunities, Manufacturers, Analysis of Top Key Players and Forecast to 2025” To Its Research Database.

Description: 

This report studies the Sanitary Napkin for Feminine Care market status and outlook of global and major regions, from angles of manufacturers, regions, product types and end industries; this report analyzes the top manufacturers in global and major regions, and splits the Sanitary Napkin for Feminine Care market by product type and applications/end industries.

For the overall market 
In the last several years, global market of Sanitary Napkin for Feminine Care developed rapidly, with an average growth rate of 7.61% during 2013 to 2017. In 2017, global revenue of Sanitary Napkin for Feminine Care is nearly 20.97 Billion USD; the actual sales are about 256303 M Unit.

The major players in global Sanitary Napkin for Feminine Care market include 
Procter & Gamble 
Kimberly-Clark 
Unicharm 
Hengan 
Johnson & Johnson 
Essity 
Kingdom Healthcare 
Kao Corporation 
Jieling 
Edgewell Personal Care Company 
Elleair 
KleanNara 
Ontex International 
Corman SpA 
Bjbest

Request for Sample Report @ https://www.wiseguyreports.com/sample-request/3239167-global-sanitary-napkin-for-feminine-care-market-research-report-2018

Geographically, this report is segmented into several key regions, with sales, revenue, market share and growth rate of Sanitary Napkin for Feminine Care in these regions, from 2013 to 2025 (forecast), covering 
North America 
Europe 
Asia-Pacific 
South America 
Middle East and Africa

On the basis of product, the Sanitary Napkin for Feminine Care market is primarily split into 
Daily Use 
Night Use

On the basis on the end users/applications, this report covers 
Supermarket 
Convenience Store 
Online Sales 
Others

Enquiry before Buying @ https://www.wiseguyreports.com/enquiry/3239167-global-sanitary-napkin-for-feminine-care-market-research-report-2018

If you have any special requirements, please let us know and we will offer you the report as you want.

Table of Content:

1 Sanitary Napkin for Feminine Care Market Overview 1 
    1.1 Sanitary Napkin for Feminine Care Product Overview 1 
    1.2 Sanitary Napkin for Feminine Care Segment by Types (Product Category) 2 
      1.2.1 Global Sanitary Napkin for Feminine Care Sales by Types 2 
      1.2.2 Global Sanitary Napkin for Feminine Care Sales Market Share by Types in 2017 3 
      1.2.3 Daily Use 4 
      1.2.4 Night Use 4 
    1.3 Global Sanitary Napkin for Feminine Care Segment by Applications 5 
      1.3.1 Global Sanitary Napkin for Feminine Care Sales Comparison by Applications 5 
      1.3.2 Supermarket 6 
      1.3.3 Convenience Store 6 
      1.3.4 Online Sales 7 
    1.4 Global Sanitary Napkin for Feminine Care Market by Regions 7 
      1.4.1 Global Sanitary Napkin for Feminine Care Market Size by Regions 7 
      1.4.2 North America Sanitary Napkin for Feminine Care Status and Prospect (2013-2025) 8 
      1.4.3 Asia-Pacific Sanitary Napkin for Feminine Care Status and Prospect (2013-2025) 9 
      1.4.4 Europe Sanitary Napkin for Feminine Care Status and Prospect (2013-2025) 10 
      1.4.5 South America Sanitary Napkin for Feminine Care Status and Prospect (2013-2025) 11 
      1.4.6 Middle East and Africa Sanitary Napkin for Feminine Care Status and Prospect (2013-2025) 12 
    1.5 Global Sanitary Napkin for Feminine Care Market Size 13 
      1.5.1 Global Sanitary Napkin for Feminine Care Revenue Status and Outlook (2013-2025) 13 
      1.5.2 Global Sanitary Napkin for Feminine Care Sales Status and Outlook (2013-2025) 14 

……..

6 Analysis of Sanitary Napkin for Feminine Care Industry Key Manufacturers 44 
    6.1 Procter & Gamble 44 
      6.1.1 Company Profile 44 
      6.1.2 Product Information 45 
      6.1.3 Sales, Price, Cost, Gross, and Revenue 46 
    6.2 Kimberly-Clark 46 
      6.2.1 Company Profile 46 
      6.2.2 Product Information 47 
      6.2.3 Sales, Price, Cost, Gross, and Revenue 48 
    6.3 Unicharm 48 
      6.3.1 Company Profile 48 
      6.3.2 Product Information 49 
      6.3.3 Sales, Price, Cost, Gross, and Revenue 50 
    6.4 Hengan 50 
      6.4.1 Company Profile 50 
      6.4.2 Product Information 51 
      6.4.3 Sales, Price, Cost, Gross, and Revenue 51 
    6.5 Johnson & Johnson 52 
      6.5.1 Company Profile 52 
      6.5.2 Product Information 53 
      6.5.3 Sales, Price, Cost, Gross, and Revenue 54 
    6.6 Essity 54 
      6.6.1 Company Profile 54 
      6.6.2 Product Information 55 
      6.6.3 Sales, Price, Cost, Gross, and Revenue 56 
    6.7 Kingdom Healthcare 56 
      6.7.1 Company Profile 56 
      6.7.2 Product Information 57 
      6.7.3 Sales, Price, Cost, Gross, and Revenue 57 
    6.8 Kao Corporation 58 
      6.8.1 Company Profile 58 
      6.8.2 Product Information 59 
      6.8.3 Sales, Price, Cost, Gross, and Revenue 59 
    6.9 Jieling 60 
      6.9.1 Company Profile 60 
      6.9.2 Product Information 61 
      6.9.3 Sales, Price, Cost, Gross, and Revenue 61 
    6.10 Edgewell Personal Care Company 62 
      6.10.1 Company Profile 62 
      6.10.2 Product Information 63 
      6.10.3 Sales, Price, Cost, Gross, and Revenue 63 
    6.11 Elleair 64 
      6.11.1 Company Profile 64 
      6.11.2 Product Information 65 
      6.11.3 Sales, Price, Cost, Gross, and Revenue 65 
    6.12 KleanNara 66 
      6.12.1 Company Profile 66 
      6.12.2 Product Information 67 
      6.12.3 Sales, Price, Cost, Gross, and Revenue 67 
    6.13 Ontex International 68 
      6.13.1 Company Profile 68 
      6.13.2 Product Information 69 
      6.13.3 Sales, Price, Cost, Gross, and Revenue 69 
    6.14 Corman SpA 70 
      6.14.1 Company Profile 70 
      6.14.2 Product Information 71 
      6.14.3 Sales, Price, Cost, Gross, and Revenue 71 
    6.15 Bjbest 72 
      6.15.1 Company Profile 72 
      6.15.2 Product Information 73 
      6.15.3 Sales, Price, Cost, Gross, and Revenue 73 

Continued…..

Norah Trent
WiseGuy Research Consultants Pvt. Ltd.
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire

Cohort Saga Selects SMART-TRIAL for Study on How Trauma Impacts Women’s Health

Jón Ingi Bergsteinsson, MEDEI’s vice-president of global business development

SMART-TRIAL software will be used in a large, decade-long nationwide research project where 110,000 Icelandic women are invited to participate

One of our most important decisions was to select a scaleable data management solution for the project. Due to the sensitive topic and large target size, we had high demands on security and usability”

— Unnur A. Valdimarsdóttir

AALBORG, DENMARK, June 19, 2018 /EINPresswire.com/ — The SAGA cohort is one of the largest research projects ever undertaken to specifically address the potential impact of trauma or severe adversities on women’s health and the potential genetic contribution to varying health trajectories after such trauma exposure. The project Cohort Saga (http://afallasaga.is/en/) is undertaken by investigators at the University of Iceland in collaboration with deCODE Genetics.

During the course of their lives, most people are exposed to trauma or severe adversities. Women are frequently subjected to violence and often it happens early in their lives. The World Health Organization estimates that one in every three women are subjected to sexual or physical violence at some point. Accumulating evidence suggests that such trauma may affect both psychological and physical health. However, large research programs are still needed to significantly advance the understanding of the complex association between trauma exposure and long-term morbidities.

In all, around 110,000 Icelandic women will be invited to participate in the SAGA cohort by answering an online questionnaire on trauma history and health and by signing an informed consent for tracking of medical diagnoses and biomarkers in existing healthcare databases and biobanks during the coming decades. The project takes advantage of MEDEI’s excellent software for data management and collection.

"One of our most important decisions was to select a scaleable data management solution for the project. Due to the sensitive topic and the large target size, we had high demands on both security and usability. We believe we made the right decision by selecting SMART-TRIAL, because it meets our requirements for both compliance and a user-friendly interface," says Unnur A. Valdimarsdóttir, Cohort Saga’s Principle Investigator and Project Guarantor.

“MEDEI is proud to be associated with such a large and prestigious humanitarian research project,” adds Jón Ingi Bergsteinsson, MEDEI’s vice-president of global business development. “Our innovative and scalable SMART-TRIAL software platform is designed for such large projects and will help Cohort Saga to simplify and better manage the on-going collection of data from this nationwide research project.”

About MEDEI

MEDEI ApS is a Danish medical software innovator that delivers industry-leading software to medical device manufacturers and clinical research. The firm’s flagship product SMART-TRIAL is a unique data management platform that helps reduce chaos and improves the collection and management of clinical data. Visit https://www.smart-trial.co

Ends

Hugh Paterson
Whoosh PR
+447768175452
email us here


Source: EIN Presswire

Blood Plasma Injections for Hair Loss and Balding: Lilac Corp Recommends Nolopecia

All natural hair loss supplement sold by Lilac Corp

Lilac Corp summarizes a paper on platelet rich plasma (PRP) treatment for hair loss, and recommends Nolopecia, a natural treatment for stimulating hair growth.

There are many treatments for hair loss on the market. However only Nolopecia targets the latent viruses that cause the increase in 5alpha-R, DHT, and AR observed in people with hair loss and balding.”

— Lilac Corp

SARASOTA, FL, UNITED STATES, June 19, 2018 /EINPresswire.com/ — A new scientific article [1] discusses the platelet-rich plasma (PRP) treatment for hair loss. PRP is prepared by taking a patient’s own blood and extracting its hair growth factors. Then, the extract is injected into the patient's scalp. This treatment has been shown to promote hair growth in several studies, especially when combined with other treatments. The article mentions two recent studies that showed that PRP increased hair growth in 60 patients over a period of 12 months. Furthermore, in 13 other studies PRP was shown to be a promising biologic treatment for hair loss. Studies also showed that hair regrowth is increased when PRP is added to a 6-month treatment of finasteride or minoxidil.

For men and women who suffer from hair loss and balding, Lilac Corp recommends the natural treatment Nolopecia. The new treatment targets the latent viruses in the body. This helps the body maintain a normal level of the 5alpha-R, DHT, and AR proteins. A normal level of these proteins stimulates hair growth. There are many treatments for hair loss on the market. However, only Nolopecia targets the latent viruses that cause the increase in 5alpha-R, DHT, and AR observed in people with hair loss and balding.

Lilac Corp is the company that invented the highly effective and unique antiviral natural treatments Gene-Eden-VIR and Novirin. For more information on these products, see lilaccorp.com, or search Google. The search will produce the clinical studies that tested the treatments and showed the safety and effectiveness of the treatments. See also references below.

About Lilac Corp:
Lilac Corp specializes in the development of biology-based patent protected natural treatments. Currently, Lilac Corp is selling four products: Gene-Eden-VIR, Novirin, Nolopecia, and Noacnin. Lilac Corp ships its products to more than 100 countries around the world. What makes Lilac Corp special is that all its products are tested in clinical studies that follow FDA guidelines. To ensure transparency, the results of the clinical studies are published in leading scientific journals. Lilac Corp also offers a 90-day money back guarantee.

Sources:
[1] Anitua E, Pino A, Jaén P, Navarro R. Platelet rich plasma for the management of hair loss: Better alone or in combination?. J Cosmet Dermatol. 2018;00:1–4.

[2] Polansky H, Javaherian A, Itzkovitz E. Clinical study in genital herpes: natural Gene-Eden-VIR/Novirin versus acyclovir, valacyclovir, and famciclovir. Drug Des Devel Ther. 2016 Aug 29;10:2713-22

[3] Polansky H, Itzkovitz E, Javaherian A. Clinical study of Gene-Eden-VIR/Novirin in genital herpes: suppressive treatment safely decreases the duration of outbreaks in both severe and mild cases. Clin Transl Med. 2016 Dec;5(1):40.

[4] Polansky H, Itzkovitz E, Javaherian A. Human papillomavirus (HPV): systemic treatment with Gene-Eden-VIR/Novirin safely and effectively clears virus. Drug Des Devel Ther. 2017 Mar 3; 11:575-583

John Evans
Lilac Corp
585-250-9999
email us here


Source: EIN Presswire

The Injectable Drug Delivery Market is expected to reach $39.6 billion by 2023

The Injectable Drug Delivery Market

The self-injection devices segment is expected to have a healthy growth rate due to factors such as growth of Biotechnology and pharmaceuticals based research.

HYDERABAD, TELANGANA, INDIA, June 19, 2018 /EINPresswire.com/ — According to the new market research report by IndustryARC titled “Injectable Drug Delivery Market By Devices, Therapeutics & Formulations [Self-Injection Devices (Pen, Needle Free &
Auto Injectors), Auto-Immune Diseases, Diabetes, Oncology, Hormonal Disorders,
Liposomes, Microspheres, Nanoparticles, Polymeric Micelles] – Forecast (2018 – 2023)”, the market is driven by the growth of the Biologics during the forecast period.

North America dominates the Injectable Drug Delivery Market

North America holds a major share in the Injectable Drug Delivery Market. In the US, chronic disease like heart diseases, diabetes, cancer, stroke, chronic obstructive pulmonary disorder, etc are prevalent. These factors drive the demand for the formulations. The number of Americans suffering from diabetes could triple by 2050.

Favourable business environment, government support, and surge of biologics propel the demand for the injectable drug delivery devices in North America.

Selected Analysis in the full Report:

Self-injection devices include auto injectors, pen injectors, and needle free injectors. These devices are used for self-administration of medication by the patients. They are used for administration of injectable drug modules such as insulin, interferon, follicle stimulating hormone, and human growth hormone. Insulin dependent diabetes is the main therapeutic area for application of self-injection devices.

The self-injection devices segment is expected to have a healthy growth rate due to factors such as growth of Biotechnology and pharmaceuticals based research. Growing incidences of diabetes is also another factor for the growth of self-injection devices.

To browse the table of contents of the report follow the link below:
https://industryarc.com/Report/1255/injectable-drug-delivery-market-analysis.html

Excerpts on Market Growth Factors

Growing diabetic population has been increasing across several regions. Diabetes can be treated by glucose monitors, insulin pumps. Usage of syringes is also used for treatment purposes.

Growing prevalence of multiple sclerosis is the main factor that enhances the demand for injectable. For treating multiple sclerosis, self-injection devices are marketed.

Injectable drug delivery is simple to deliver due to the large molecular size of Biologics and its high effectiveness. This factor drives the demand for drug delivery devices.

Talk to one of our sales representative about the full report by providing your details in the link below:
https://industryarc.com/support.php?id=1255

Key players of the Injectable Drug Delivery Market

Becton Dickinson & Co, Baxter International, Terumo Corporation, Schott AG dominate the Injectable Drug Delivery Market. The other players include West Pharmaceutical Services, Unilife Corporation, Gerresheimer AG, and B Braun Melsungen AG.

Becton Dickinson & Co is a company with advanced medical technology engaged in development, manufacture, and sale of devices, instrument systems, diagnostic products, etc. Baxter International manufactures medical devices, pharmaceuticals, and Biotechnology products. Schott AG operates in the business segments such as solar power, electronic packaging, fiber optics, pharmaceutical systems, home tech, and flat glass.

Unilife Corporation which is headquartered in Pennsylvania focuses on the manufacture and supply of injectable drug delivery systems.

Companies Citied / Interviewed

1.ALKERMES, INC.
2.ANTARES PHARMA, INC.
3.BAXTER INTERNATIONAL, INC.
4.BECTON, DICKINSON AND COMPANY
5.BESPAK EUROPE, LTD
6.CROSSJECT SA
7.ELCAM MEDICAL
8.ELI LILLY AND COMPANY
9.GERRESHEIMER AG
10.HASELMEIER GMBH
11.INJEX PHARMA GMBH
12.NOVO NORDISK A/S
13.OWEN MUMFORD, LTD.
14.SANOFI
15.Company 15
16.Company 16+

Related Report:

A.Connected Injectable Drug Delivery Devices Market
https://industryarc.com/Report/18040/connected-injectable-drug-delivery-devices-market.html

B.Self-Testing and Self Injectable Devices Market
https://industryarc.com/Report/17015/self-testing-self-injectable-devices-market.html

Injectable Drug Delivery Market is segmented as below

A. Injectable Drug Delivery Market By Drug Formulations
1. Conventional Drug Delivery Formulations
1.1. Injectable Drug Delivery Formulation Solutions
1.2. Reconstituted Drug Delivery Formulation Solutions

2. Novel Drug Delivery Formulation Solutions
2.1. Liposomal Systems
2.2. Microspheres
2.3. Nanoparticles
2.4. Polymeric Micelles
2.5. Others

B. Injectable Drug Delivery Market By Therapeutic areas

1. Auto-Immune Diseases
1.1. Multiple Sclerosis
1.2. Rheumatoid Arthritis
1.3. Crohn's Diseases
1.4. Psoriasis
1.5. Others
2. Hormonal Disorders
2.1. Diabetes
2.2. Anemia
2.3. Reproductive Health Diseases
2.4. Osteoporosis
2.5. Growth Hormone Deficiency
2.6. Antithrombotic Therapy
3. Orphan Or Rare Diseases
4. Oncology
5. Others
5.1. Pain Management
5.2. Hepatitis C
5.3. Allergies
5.4. Aesthetic Treatment

C. Injectable Drug Delivery Market by Geography (covers 9+ countries)
E. Injectable Drug Deliver Market Entropy

What can you expect from the report?
The Injectable Drug Delivery Market Report is Prepared with the Main Agenda to Cover the following 20 points:

1. Market Size by Product Categories & Application 11. Demand Analysis (Revenue & Volume)
2. Market trends & Relevant Market Data 12. Country level Analysis
3. Manufacturer Landscape 13. Competitor Analysis
4. Distributor Landscape 14. Market Shares Analysis
5. Pricing Analysis 15. Value Chain Analysis
6. Top 10 End user Analysis 16. Supply Chain Analysis
7. Product Benchmarking 17. Strategic Analysis
8. Product Developments 18. Current & Future Market Landscape Analysis
9. Mergers & Acquisition Analysis 19. Opportunity Analysis
10. Patent Analysis 20. Revenue and Volume Analysis

To request for a proposal, provide your details in the below link:
https://industryarc.com/subscription.php

About IndustryARC:

IndustryARC is a Research and Consulting Firm that publishes more than 500 reports annually, in various industries such as Agriculture, Automotive, Automation & Instrumentation, Chemicals and Materials, Energy and Power, Electronics, Food & Beverages, Information Technology, Life sciences &Healthcare.

IndustryARC primarily focuses on Cutting Edge Technologies and Newer Applications in a Market. Our Custom Research Services are designed to provide insights on the constant flux in the global supply-demand gap of markets. Our strong team of analysts enables us to meet the client research needs at a rapid speed, with a variety of options for your business.
We look forward to support the client to be able to better address their customer needs, stay ahead in the market, become the top competitor and get real-time recommendations on business strategies and deals. Contact us to find out how we can help you today.

Venkat Reddy
IndustryARC
6145888538
email us here


Source: EIN Presswire

Hemostatic Agents Market is anticipated to hit $8.94 billion by 2023 at a CAGR of 7.10%

Hemostatic Agents Market

The American region holds the largest market share and growth in the Hemostatic agents Market and is anticipated to reach $4.7 billion by 2023 at CAGR of 7.20%

HYDERABAD, TELANGANA, INDIA, June 19, 2018 /EINPresswire.com/ — According to the new market research report by IndustryARC titled “Hemostatic Agents Market: By Type (Thrombin, Oxidized Regenerated Cellulose, Combination, Gelatin, Collagen, Fibrin Sealants); By Treatment (Cardiovascular, General, Digestive, Neurological); By End User (Hospitals, Surgical Centers, Nursing Homes) & Geography – Forecast (2016-2022)”, the market is driven by the increase in surgical procedures across the globe coupled with the rise in the number of insurance providers propelling the Hemostats Market. Increase in hospital facilities with government initiatives is another reason driving the growth of the Hemostats Market.

Americas held the largest market share in the Hemostatic Agents Market
The American region holds the largest market share and growth in the Hemostatic agents Market and is anticipated to reach $4.7 billion by 2023 at a CAGR of 7.20%. However, APAC registers the highest growth and is anticipated to reach $1.6 billion at a CAGR of 11.4%. The American region is the dominant market for hemostats market due to its growing technological advancements, and need for enhancing the patient safety. The key end-users in this region include Hospitals, Surgery Centers, and Nursing Homes.

Selected Market Share Analysis done in the full report
As per IndustryARC analysts, manufacturers in Hemostats are estimated to take a leap in the production of these products owing to the increasing demand from the medical segment.
The market share analysis has been done considering the revenue of Hemostats suppliers. The market is fairly fragmented with small companies accounting for a combined share of 52% in terms of revenue.
Some big companies have significant presence in this market mainly due to their strong clientele in the commercial sector and strong manufacturing capability.
The suppliers of the market continue to evolve to meet the challenges of technology, growing consumer demands, increased emphasis on sustainable products, globalization, cost pressures, growing healthcare sector, increasing population and more.

To browse the table of contents of the report follow the link below:
https://industryarc.com/Report/15189/hemostats-market.html

Excerpts on Market Growth Factors
High requirement for spinal surgeries have resulted in an increased growth rate for hemostats in U.S. market.
Other growth factors include technological advancements alongside increasing hospitals and healthcare facilities, which ultimately resulted in adoption of advanced surgical equipment in surgeries.
The adoption rate of hemostats was attributed to the aging population, as this is an important procedure to prevent blood loss in the patients.
Amongst various end users, hospitals generated the highest revenue and is anticipated to reach $4.5 billion by 2022
Rising awareness about the advanced equipment among the public, increased spending in healthcare, growing use of artificial devices in operations is resulting in the growth of the hemostats market.

Talk to one of our sales representative about the full report by providing your details in the below link:
https://industryarc.com/Report/15189/hemostats-market.html

Key players of Hemostatic Agents Market:
Johnson & Johnson is one of the leading suppliers in the Hemostats market, contributing to nearly 17% of the overall revenue. Johnson & Johnson through its broad range of products, constant product launches and innovation have been successful in catering to a variety of customers, consequently maintaining their hold over the market.
However, monitoring their future business involvements, IndustryARC analysts anticipate companies such as Baxter, Pfizer, Braun, C.R. Bard, CSL Behring and more to maintain their position in the market.
Baxter International holds second major share in the Hemostats market.
Baxter International Incorporation, Mallinckrodt Plc, C.R. Brad Incorporation, Integra Life Sciences Corporation and others are the names of few companies involved in acquisition strategies.

Hemostatic Agents Market Report is segmented as indicated below
Hemostatic Agents Market By Type:
1.Thrombin Based Hemostats
2.Gelatin Based Hemostats
3.Collagen Based Hemostats
4.Oxidized Based Hemostats
5.Combination Hemostats
6.Fibrin Hemostats
7.Others
Hemostatic Agents Market By Treatment
1.Cardiovascular
2.General Surgery
3.Digestive Surgery
4.Neurosurgery
5.Others
Hemostatic Agents Market By End User
1 Hospitals
2 Surgery Centers
3 Nursing Homes
4 Others
Hemostatic Agents Market By Geography (Covers 13 + Countries)
Hemostatic Agents Market By Entropy

Companies Cited/Referenced/Interviewed:
1.B. Braun Melsungen
2.Integra Life Sciences Corporation
3.Equimedical B.V.
4.Marine Polymer Technologies Inc.
5.Gelita GmBh
6.Johnson and Johnson Services
7.Pfizer Inc;
8.Advanced Medical Solutions Group (Resorba Wundversorgung)
9.Vascular Solutions Inc;
10.Z-Medica LLC
11.Mallinckrodt PLC
12.Company 12
13.Company 13
14.Company 14
15.Company 15+
Related Reports
A.Hemodynamic Monitoring System Market
https://industryarc.com/Report/10602/hemodynamic-monitoring-system-market.html

B.Blood Culture Tests Market
https://industryarc.com/Report/10633/blood-culture-tests-market.html

What can you expect from the report?
The Hemostatic Agents Market is Prepared with the Main Agenda to Cover the following 20 points:
1.Market Size by Product Categories
2.Market trends
3.Manufacturer Landscape
4.Distributor Landscape
5.Pricing Analysis
6.Top 10 End user Analysis
7.Product Benchmarking
8.Product Developments
9.Mergers & Acquisition Analysis
10.Patent Analysis
11.Demand Analysis (By Revenue & Volume)
12.Country level Analysis (15+)
13.Competitor Analysis
14.Market Shares Analysis
15.Value Chain Analysis
16.Supply Chain Analysis
17.Strategic Analysis
18.Current & Future Market Landscape Analysis
19.Opportunity Analysis
20.Revenue and Volume Analysis

To request for a proposal provide your details in the below link:
https://industryarc.com/subscription.php

About IndustryARC:

IndustryARC is a Research and Consulting Firm that publishes more than 500 reports annually, in various industries such as Agriculture, Automotive, Automation & Instrumentation, Chemicals and Materials, Energy and Power, Electronics, Food & Beverages, Information Technology, Life sciences &Healthcare.

IndustryARC primarily focuses on Cutting Edge Technologies and Newer Applications in a Market. Our Custom Research Services are designed to provide insights on the constant flux in the global supply-demand gap of markets. Our strong team of analysts enables us to meet the client research needs at a rapid speed, with a variety of options for your business.
We look forward to support the client to be able to better address their customer needs, stay ahead in the market, become the top competitor and get real-time recommendations on business strategies and deals. Contact us to find out how we can help you today.

Venkat Reddy
IndustryARC
6145888538
email us here


Source: EIN Presswire